Substantial evidences suggest that the increased cerebral deposition, and neurotoxic action
of the β-amyloid peptide, the major constituent of senile plaques, may represent the …

Praise for the First Edition of Design and Analysis of Clinical Trials" An excellent book,
providing a discussion of the clinical trial process from designing the study through …

Objective.—To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30
weeks in patients with probable Alzheimer's disease. Design.—A 30-week randomized …

Context Cholinesterase inhibitors are the primary treatment for the cognitive symptoms of
Alzheimer disease (AD). Cholinergic dysfunction is also associated with neuropsychiatric …

Society today, writes Stephen Post, is" hypercognitive": it places inordinate emphasis on
people's powers of rational thinking and memory. Thus, Alzheimer disease and other …

Huperzine A (HupA), a novel alkaloid isolated from the Chinese herb Huperzia serrata, is a
potent, highly specific and reversible inhibitor of acetylcholinesterase (AChE). Compared …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …

Objective: To describe the prevalence of cognitive impairment among elderly primary care
patients and to compare diagnostic evaluations and use of health services among patients …

Apolipoprotein E (apoE) is critical in the modulation of cholesterol and phospholipid
transport between cells of different types. Human apoE is a polymorphic protein with three …

Biomarkers have a key role in Alzheimer's disease (AD) drug development. Biomarkers can
assist in diagnosis, demonstrate target engagement, support disease modification, and …